文献速递肝病食管胃疾病与幽门螺杆菌

腹腔CD206水平与失代偿期肝硬化合并自发性细菌性腹膜炎患者死亡率及炎性巨噬细胞表型相关

Peritoneal Level of CD206 Associates With Mortality and an Inflammatory Macrophage Phenotype in Patients With Decompensated Cirrhosis and Spontaneous Bacterial Peritonitis.
PubMed 文献 · Gastroenterology · 2020-01-23

研究从66例失代偿期肝硬化患者(19例SBP)腹水中分离腹腔巨噬细胞,用流式细胞术、qPCR、功能分析和RNA微阵列分析,发现CD206可区分大腹腔巨噬细胞(LPM)和小腹腔巨噬细胞(SPM),LPM呈炎性表型且释放更多TNF。在111例测试队列(67例SBP)和71例验证队列中,腹水可溶性CD206>0.53 mg/L的SBP患者90天生存率更低。

要点

  • CD206表面水平可区分肝硬化患者腹水中成熟、驻留的炎性LPM与SPM。
  • LPM具有炎性表型,不易诱导耐受,释放TNF多于SPM。
  • SBP患者腹水可溶性CD206>0.53 mg/L与90天生存率降低相关。

核心结论

  • CD206表面水平可用于识别肝硬化患者成熟、驻留的炎性腹腔巨噬细胞。
  • 可溶性CD206由活化的LPM释放,肝硬化合并SBP患者腹水中浓度升高提示90天生存几率降低。

研究设计与样本

  • 从66例失代偿期肝硬化患者(19例SBP)腹水中分离腹腔巨噬细胞,进行流式细胞术、qPCR、功能分析和RNA微阵列分析。
  • 测试队列为111例失代偿期肝硬化患者(67例SBP),用ELISA定量腹水可溶性CD206和TNF,用logistic回归分析90天死亡率相关因素。
  • 验证队列为71例肝硬化合并SBP患者,并以14例无肝硬化的腹膜透析终末期肾病患者作为对照。

主要发现

  • 用CD206表面水平识别出大腹腔巨噬细胞(LPM)和小腹腔巨噬细胞(SPM),两者颗粒度和成熟标志物不同。
  • LPM与SPM转录组不同,鉴定出超过4000个差异调节基因,涉及细胞周期、代谢、自我更新和免疫细胞信号。
  • LPM具有炎性表型,不易诱导耐受,释放TNF多于SPM;肝硬化患者LPM产生的炎性细胞因子多于对照LPM。
  • Toll样受体激动剂和活菌激活PMs可改变LPM表面CD206水平及可溶性CD206释放。
  • SBP患者连续腹水分析显示早期LPM丢失,治疗后水平增加。

关键数值与推荐

  • 腹水可溶性CD206阈值为>0.53 mg/L,用于区分SBP患者90天生存率。

临床怎么用

  • 腹水可溶性CD206>0.53 mg/L或可辅助识别肝硬化合并SBP后90天死亡风险较高的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Peritoneal macrophages (PMs) regulate inflammation and control bacterial infections in patients with decompensated cirrhosis. We aimed to characterize PMs and associate their activation with outcomes of patients with spontaneous bacterial peritonitis (SBP). METHODS: We isolated PMs from ascites samples of 66 patients with decompensated cirrhosis (19 with SBP) and analyzed them by flow cytometry, quantitative real-time polymerase chain reaction, functional analysis, and RNA microarrays. We used ascites samples of a separate cohort of 111 patients with decompensated cirrhosis (67 with SBP) and quantified the soluble form of the mannose receptor (CD206) and tumor necrosis factor by enzyme-linked immunosorbent assay (test cohort). We performed logistic regression analysis to identify factors associated with 90-day mortality. We validated our findings using data from 71 patients with cirrhosis and SBP. Data from 14 patients undergoing peritoneal dialysis for end-stage renal disease but without cirrhosis were included as controls. RESULTS: We used surface levels of CD206 to identify subsets of large PMs (LPM) and small PMs (SPM), which differed in granularity and maturation markers, in ascites samples from patients with cirrhosis. LPMs vs SPMs from patients with cirrhosis had different transcriptomes; we identified more than 4000 genes that were differentially regulated in LPMs vs SPMs, including those that regulate the cycle, metabolism, self-renewal, and immune cell signaling. LPMs had an inflammatory phenotype, were less susceptible to tolerance induction, and released more tumor necrosis factor than SPMs. LPMs from patients with cirrhosis produced more inflammatory cytokines than LPMs from controls. Activation of PMs by Toll-like receptor agonists and live bacteria altered levels of CD206 on the surface of LPMs and release of soluble CD206. Analysis of serial ascites fluid from patients with SBP revealed loss of LPMs in the early phase of SBP, but levels increased after treatment. In the test and validation cohorts, patients with SBP and higher concentrations of soluble CD206 in ascites fluid (>0.53 mg/L) were less likely to survive for 90 days than those with lower levels. CONCLUSIONS: Surface level of CD206 can be used to identify mature, resident, inflammatory PMs in patients with cirrhosis. Soluble CD206 is released from activated LPMs and increased concentrations in patients with cirrhosis and SBP indicate reduced odds of surviving for 90 days.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Stengel S, Quickert S, Lutz P, et al. Peritoneal Level of CD206 Associates With Mortality and an Inflammatory Macrophage Phenotype in Patients With Decompensated Cirrhosis and Spontaneous Bacterial Peritonitis. Gastroenterology. 2020. PMID: 31982413. doi:10.1053/j.gastro.2020.01.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。